Elevated peripheral and nervous system inflammation is associated with decreased short-chain fatty acid levels in Zika virus-infected macaques

/in

Schroeder TA, Manuzak JA, Miller CJ, Gustin AT, Basting CM, Cheu RK, Velez A, Driscoll CB, Tisoncik-Go J, Schifanella L, Hensley-McBain T, Evandy CA, Smith EA, Bratt D, Shields-Cutler R, Smedley J, Fuller DH, Barouch DH, O’Connor MA, Gale M, Klatt NR.2025.Elevated peripheral and nervous system inflammation is associated with decreased short-chain fatty acid levels in Zika virus-infected macaques. J Virol99:e01003-25.https://doi.org/10.1128/jvi.01003-25

Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques

/in

Jacob-Dolan C, Hope D, Liu J, Waller-Pulido A, Verrette B, Cabrera-Barragan DN, Nangle SJ, Wang Q, Blanc R, Fisher J, Lasrado N, Wang L, Cook A, Pessiant L, Lewis M, Andersen H, Hopps M, Scully IL, Allen PS, McNamara RP, Anderson AS, Barouch DH. Adenovirus and mRNA vaccines as well as mucosal boosting improve protective efficacy against influenza virus challenge in macaques. Sci Transl Med. 2025 Jul 9;17(806):eadu7646. doi: 10.1126/scitranslmed.adu7646. Epub 2025 Jul 9.

Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis

/in

Chapman A, Barouch DH, Lip GYH, Pliakas T, Polverino E, Sourij H, Abduljawad S. Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2025 Sep;158:107958. doi: 10.1016/j.ijid.2025.107958. Epub 2025 Jun 24.

Mucosal boosting increases protective efficacy of an influenza vaccine in mice

/in

Wang L, Chan CN, Chaudhari J, Hope D, Espinosa Perez AA, Lasrado N, Li Z, Waller-Pulido A, Cabrera-Barragan DN, Verrette B, Nangle SJ, Ayala-Bernot J, Jacob-Dolan C, Lifton M, Strutton E, Fisher J, Mbiwan E, Rossler A, Schrag S, Barouch DH. Mucosal boosting increases protective efficacy of an influenza vaccine in mice. iScience. 2025 May 21;28(6):112721. doi: 10.1016/j.isci.2025.112721.

Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial

/in

Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF; HVTN 140/HPTN 101 study team. Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial. Lancet HIV. 2025 Jun;12(6):e405-e415. doi: 10.1016/S2352-3018(25)00012-8.

Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data

/in

Andrews LIB, Halloran ME, Neuzil KM, van der Laan L, Huang Y, Andriesen J, Patel M, Fisher LH, Janes H, Rouphael N, Walsh SR, Theodore DA, Tieu HV, Sobieszczyk M, El Sahly HM, Baden LR, Falsey AR, Campbell TB, Kelley CF, Healy CM, Immergluck L, Luft B, Hirsch I, de Bruyn G, Truyers C, Priddy F, Sumner KM, Flannery B, Follmann D, Gilbert PB; COVID-19 Prevention Network (CoVPN). Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials. JAMA Netw Open. 2025 May 1;8(5):e2512763. doi: 10.1001/jamanetworkopen.2025.12763

SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

/in

Sambaturu N, Fray EJ, Hariharan V, Wu F, Zitzmann C, Simonetti FR, Barouch DH, Siliciano JD, Siliciano RF, Ribeiro RM, Perelson AS, Molina-París C, Leitner T. SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells. Cell Reports. 2025 May 27;44(5):115663. doi: 10.1016/j.celrep.2025.115663. Epub 2025 May 5.

Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice

/in , ,

Blass, E., Colarusso, A., Aid, M., Larocca, R. A., Reeves, R. K., & Barouch, D. H. (2025). Early spatiotemporal evolution of the immune response elicited by adenovirus serotype 26 vector vaccination in mice. Journal of virology, 99(5), e0024725. https://doi.org/10.1128/jvi.00247-25

On-patient medical record and mRNA therapeutics using intradermal microneedles

/in

Han, J., Kanelli, M., Liu, Y., Daristotle, J. L., Pardeshi, A., Forster, T. A., Karchin, A., Folk, B., Murmann, L., Tostanoski, L. H., Carrasco, S. E., Alsaiari, S. K., Wang, E. Y., Tran, K., Zhang, L., Eshaghi, B., Levy, L., Pyon, S., Sloane, C., Lin, S. Q., … Jaklenec, A. (2025). On-patient medical record and mRNA therapeutics using intradermal microneedles. Nature materials, 24(5), 794–803. https://doi.org/10.1038/s41563-024-02115-4

Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV

/in ,

Chawana, T. D., Walsh, S. R., Stranix-Chibanda, L., Chirenje, Z. M., Yu, C., Zhang, L., Seaton, K. E., Heptinstall, J., Zhang, L., Paez, C. A., Gamble, T., Karuna, S. T., Andrew, P., Hanscom, B., Sobieszczyk, M. E., Edupuganti, S., Gay, C. L., Mannheimer, S. B., Hurt, C. B., Stephenson, K. E., … HVTN 127/HPTN 087, HVTN 130/HPTN 089 and HVTN 136/HPTN 092 Study Teams (2025). Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV. BMC immunology, 26(1), 8. https://doi.org/10.1186/s12865-025-00687-7